key: cord-0742326-gom2f8qt
authors: Vetter, Pauline; Cordey, Samuel; Schibler, Manuel; Vieux, Laure; Despres, Lena; Laubscher, Florian; Andrey, Diego O.; Martischang, Romain; Harbarth, Stephan; Cuvelier, Clémence; Bekliz, Meriem; Eckerle, Isabella; Siegrist, Claire-Anne; Didierlaurent, Arnaud M.; Eberhardt, Christiane S.; Meyer, Benjamin; Kaiser, Laurent
title: Clinical, virological and immunological features of a mild case of SARS-CoV-2 re-infection
date: 2021-02-20
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2021.02.010
sha: 82038f11bfc8830039a9bd7351e2b7ca9e30e846
doc_id: 742326
cord_uid: gom2f8qt

OBJECTIVES: We report a case of SARS-CoV-2 reinfection 6 months after the first infection in a young healthy female physician. Both episodes led to mild COVID-19. METHODS: SARS-CoV-2 infections was detected by RT-PCR on naso-pharyngeal specimens. Reinfection was confirmed by whole-genome sequencing. Kinetics of total anti-S receptor binding domain immunoglobulins (Ig anti-S RBD), anti-nucleoprotein (anti-N) and neutralizing antibodies were determined in serial serum samples retrieved during both infection episodes. Memory B cells responses were assessed at day 12 post reinfection. RESULTS: Whole-genome sequencing identified two different SARS-CoV-2 genomes both belonging to clade 20A, with only one non-synonymous mutation in the spike protein, and clustered with viruses circulating in Geneva (Switzerland) at the time of each of the corresponding episodes. Seroconversion was documented with low level of total Ig anti-S RBD and anti-N antibodies at one month after the first infection whereas neutralizing antibodies quickly declined after the first episode and then were boosted by the reinfection, with high titers detectable 4 days after symptoms onset. A strong memory B cell response was detected at day 12 post onset of symptoms during reinfection, indicating that the first episode elicited cellular memory responses. CONCLUSION: Rapid decline of neutralizing antibodies may put medical personnel at risk of reinfection as shown in this case. Reinfection however leads to a significant boosting of previous immune responses. Larger cohorts of reinfected subjects with detailed descriptions of their immune responses are needed to define correlates of protection and their duration after infection.

Objectives: 34 We report a case of SARS-CoV-2 reinfection 6 months after the first infection in a young healthy 35 female physician. Both episodes led to mild COVID-19. On April 10, 2020, a 36 year-old asymptomatic female physician tested positive for SARS-CoV-81 2 (viral load of 1.26E+05 copies/ml) on a NPS collected during an active nosocomial outbreak 82 investigation ( Figure 1A ). Two days later, she developed asthenia, headache lasting for two 83 weeks, and experienced slight memory loss and difficulties concentrating upon resuming work.

Independently of this episode, she was enrolled in a longitudinal cohort study assessing the 85 seroprevalence of COVID-19 in health care workers (HCW) at our institution and sequential 86 serum sampling was performed, starting one week prior the first episode. Anti-S1 IgG were 87 negative 7 days before the first infection and seroconversion was confirmed at day 14 and one 88 month post infection with anti-S1 IgG and total immunoglobulins directed against the 89 nucleoprotein (anti-N Ig) and against the receptor-binding-domain of the spike protein (anti-S-90 RBD Ig) at low but increasing titers over time ( Figure 1B ). On October 15 th , another nosocomial 91 cluster was identified, and she was tested again as part of hospital surveillance. She was 92 asymptomatic and her RT-PCR was negative. On October 30 th , while still working in a COVID-93 19 ward, she developed asthenia, followed by shivering, rhinorrhea, anosmia, arthralgia, 94 headache and exertional dyspnea. The next day, the RT-PCR was positive (viral load of 95 2.94E+07 copies/mL), and was confirmed by a second NPS taken 4 days later, showing a rapid Here, the supposed mechanism leading to reinfection is a loss of protection elicited after the first 132 episode, as it is known for other human coronaviruses [9] . The only mutation found in the spike 133 region between the two episodes has not been associated with reduced neutralization by human 134 convalescent sera [10] . In vitro, this mutation may lead to monoclonal antibodies neutralization 135 resistance but whether this is relevant for human reinfections remains to be studied. Of note, it 136 was not possible to assess whether the reinfection may have been the consequence of exposure to 137 a high viral inoculum.

As per local recommendations, HCW are asked to get tested when displaying symptoms 139 compatible with COVID-19. In our institution, more than 700 HCW were infected in the [11], all leading to a second mild COVID-19; as many other cases reported in the literature, these cases are imperfectly documented. With only few reports in the literature, SARS-CoV-2 146 reinfection seems to be rare within the first 6 months after 4, 12, 13] . Based on 147 seasonal coronaviruses immunity, we can expect that reinfection will be increasingly common 

Genomic evidence for reinfection with SARS-CoV-2: a case study

Asymptomatic reinfection in two healthcare workers from India with genetically 204 distinct SARS-CoV-2

COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain 206 confirmed by whole genome sequencing

Reinfection of SARS-CoV-2 in an immunocompromised patient: a case report

SARS-CoV-2 viral load in the upper respiratory tract of children and adults with 210 early acute COVID-19

Daily Viral Kinetics and Innate and Adaptive Immune Response Assessment in 212 COVID-19: a Case Series. mSphere

Emergence and spread of a SARS-CoV-2 variant through Europe in the 214 summer of 2020. medRxiv

Serum antibody profile of a patient with COVID-19 reinfection

Seasonal coronavirus protective immunity is short-lasting

Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that 220 attenuate monoclonal and serum antibody neutralization. bioRxiv

Definitions for COVID-19 reinfection, relapse and PCR re-positivity. Clin 222 Microbiol Infect

A Case of Early Re-infection with SARS-CoV-2

Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 226 patients and healthy volunteers up to 6 months post disease onset

We thank Erik Boehm for editorial assistance. We thank Sabine Yerly for her meaningful 163 insights. We are deeply grateful to our colleague from whom informed consent to publish the 164 case report has been obtained. Faculty of Medicine. The funder had no role in study design, data collection, data analysis, data 175 interpretation or writing of the report. The corresponding author had full access to all the data in 176 the study and had final responsibility for the decision to submit for publication.

The authors declare no conflict of interest.